Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

Last week, the Dow Jones Industrial Average and the S&P 500 gained a marginal 0.7% and 0.5%, respectively. The Nasdaq Composite's gain was also negligible. Investors adopted a cautious approach last week before the annual Jackson Hole Economic Policy Symposium event that concluded on Aug 24, 2024. The broader markets moved sideways. U.S. Federal Reserve Chairman Jerome Powell, in his keynote speech, talked about imminent policy easing after holding the key lending rate at a two-decade high for more than a y ...

ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Ea ...

Shares of TransMedics (TMDX) have been strong performers lately, with the stock up 12% over the past month. The stock hit a new 52-week high of $175.73 in the previous session. TransMedics has gained 111.7% since the start of the year compared to the 10.1% move for the Zacks Medical sector and the 8.3% return for the Zacks Medical - Instruments industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...

A long lead in a niche industry ripe for disruption could make this stock a top performer. For longer than most folks reading this have been alive, Warren Buffett has been getting rich by acting greedy while the rest of the market is fearful. According to one popular indicator, it's nearly time to start acting greedy. A key measure of stock market fear, the CBOE S&P 500 Volatility Index, or VIX, spiked above 60 points on the morning of Monday, Aug. 5. That's higher than it's been since the COVID-19 pandemic ...

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend. A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages ...

CatLane Back in October 2023, I was adding aggressively to my TransMedics Group, Inc. (NASDAQ:TMDX) position when the stock dipped into the $30s. I was also adding aggressively before Q1 2024 earnings. Back in March/April, as I was trimming 90-95% of my Celsius Holdings, Inc. (CELH) and Super Micro Computer, Inc. (SMCI) positions, I was using that cash to add to many of my holdings, including TMDX. It became my largest position, and it's been that way for approximately three months. Even though TMDX is up m ...

TransMedics (TMDX) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. Analysts' growing optimism on the earnings prospects of this medical technology company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earn ...

sturti TransMedics Group (NASDAQ:TMDX) had a remarkable second quarter, with another beat & raise. It's tough to say what the market thinks of the results, as the stock initially popped double-digits in the after-hours, but then came back down to being up just ~6% as the broad market sell-off intensified. There are three key questions I'm monitoring as TransMedics continues to execute its long-term plan. Let's dive in. Introduction To TransMedics I wrote my first article covering TransMedics back in March, ...

For the quarter ended June 2024, TransMedics (TMDX) reported revenue of $114.31 million, up 117.9% over the same period last year. EPS came in at $0.35, compared to -$0.03 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $98.63 million, representing a surprise of +15.89%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being $0.21. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...